{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:21:07Z","timestamp":1783041667664,"version":"3.54.6"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS KAKENHI","award":["JP21K09863"],"award-info":[{"award-number":["JP21K09863"]}]},{"name":"JSPS KAKENHI","award":["JP24K12891"],"award-info":[{"award-number":["JP24K12891"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-026-01568-w","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:10:58Z","timestamp":1783041058000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytokine Networks Reprogramming the Osteo\u2013Immune Microenvironment in Cancer Bone Metastasis"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7829-2395","authenticated-orcid":false,"given":"Toru","family":"Hiraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"1568_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","volume":"6","author":"RE Coleman","year":"2020","unstructured":"Coleman RE, Croucher PI, Padhani AR et al (2020) Bone metastases. Nat Rev Dis Prim 6:83. https:\/\/doi.org\/10.1038\/s41572-020-00216-3","journal-title":"Nat Rev Dis Prim"},{"key":"1568_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","volume":"43","author":"CT Kureshi","year":"2025","unstructured":"Kureshi CT, Dougan SK (2025) Cytokines in cancer. Cancer Cell 43:15\u201335. https:\/\/doi.org\/10.1016\/j.ccell.2024.11.011","journal-title":"Cancer Cell"},{"key":"1568_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR (2022) Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol 19:237\u2013253. https:\/\/doi.org\/10.1038\/s41571-021-00588-9","journal-title":"Nat Rev Clin Oncol"},{"key":"1568_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41584-025-01323-9","volume":"22","author":"M Rauner","year":"2026","unstructured":"Rauner M, Bozec A (2026) Mechanisms of osteoclast activation in inflammatory bone loss in rheumatoid arthritis. Nat Rev Rheumatol 22:42\u201361. https:\/\/doi.org\/10.1038\/s41584-025-01323-9","journal-title":"Nat Rev Rheumatol"},{"key":"1568_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3892\/ijo.2024.5623","volume":"64","author":"T Hiraga","year":"2024","unstructured":"Hiraga T (2024) Immunotherapy targeting PD-1\/PD-L1: a potential approach for the treatment of cancer bone metastases. Int J Oncol 64:35. https:\/\/doi.org\/10.3892\/ijo.2024.5623","journal-title":"Int J Oncol"},{"key":"1568_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117328","volume":"191","author":"T Hiraga","year":"2025","unstructured":"Hiraga T (2025) Immune microenvironment of cancer bone metastasis. Bone 191:117328. https:\/\/doi.org\/10.1016\/j.bone.2024.117328","journal-title":"Bone"},{"key":"1568_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101224","volume":"69","author":"E Massy","year":"2025","unstructured":"Massy E, Confavreux CB, Point M et al (2025) Contribution of the immune bone marrow microenvironment to tumor growth and bone deconstruction: implications for improving immunotherapeutic strategies in bone metastasis. Neoplasia 69:101224. https:\/\/doi.org\/10.1016\/j.neo.2025.101224","journal-title":"Neoplasia"},{"key":"1568_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4161\/onci.1.2.18480","volume":"1","author":"E Zhao","year":"2012","unstructured":"Zhao E, Wang L, Dai J et al (2012) Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology 1:152\u2013161. https:\/\/doi.org\/10.4161\/onci.1.2.18480","journal-title":"Oncoimmunology"},{"key":"1568_CR9","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.18632\/oncotarget.27817","volume":"11","author":"E Heninger","year":"2020","unstructured":"Heninger E, Sethakorn N, Kosoff D et al (2020) Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer. Oncotarget 11:4253\u20134265. https:\/\/doi.org\/10.18632\/oncotarget.27817","journal-title":"Oncotarget"},{"key":"1568_CR10","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1158\/1541-7786.MCR-21-0243","volume":"19","author":"T Hiraga","year":"2021","unstructured":"Hiraga T, Ito S, Mizoguchi T (2021) Opposing effects of granulocyte colony-stimulating factor on the initiation and progression of breast cancer bone metastases. Mol Cancer Res 19:2110\u20132119. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0243","journal-title":"Mol Cancer Res"},{"key":"1568_CR11","doi-asserted-by":"publisher","first-page":"8970173","DOI":"10.1155\/2021\/8970173","volume":"2021","author":"C Liu","year":"2021","unstructured":"Liu C, Wang M, Xu C et al (2021) Immune checkpoint inhibitor therapy for bone metastases: specific microenvironment and current situation. J Immunol Res 2021:8970173. https:\/\/doi.org\/10.1155\/2021\/8970173","journal-title":"J Immunol Res"},{"key":"1568_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70788-3","volume":"10","author":"L Monteran","year":"2020","unstructured":"Monteran L, Ershaid N, Sabah I et al (2020) Bone metastasis is associated with acquisition of mesenchymal phenotype and immune suppression in a model of spontaneous breast cancer metastasis. Sci Rep 10:13838. https:\/\/doi.org\/10.1038\/s41598-020-70788-3","journal-title":"Sci Rep"},{"key":"1568_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-024-05772-y","volume":"7","author":"F Ma","year":"2024","unstructured":"Ma F, Wang S, Xu L et al (2024) Single-cell profiling of the microenvironment in human bone metastatic renal cell carcinoma. Commun Biol 7:91. https:\/\/doi.org\/10.1038\/s42003-024-05772-y","journal-title":"Commun Biol"},{"key":"1568_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/imr.13272","volume":"321","author":"P Holicek","year":"2024","unstructured":"Holicek P, Guilbaud E, Klapp V et al (2024) Type I interferon and cancer. Immunol Rev 321:115\u2013127. https:\/\/doi.org\/10.1111\/imr.13272","journal-title":"Immunol Rev"},{"key":"1568_CR15","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1152\/physrev.00047.2024","volume":"105","author":"CP Mavragani","year":"2025","unstructured":"Mavragani CP, Crow MK (2025) Type I interferons in health and disease: molecular aspects and clinical implications. Physiol Rev 105:2537\u20132587. https:\/\/doi.org\/10.1152\/physrev.00047.2024","journal-title":"Physiol Rev"},{"key":"1568_CR16","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/nm.2830","volume":"18","author":"BN Bidwell","year":"2012","unstructured":"Bidwell BN, Slaney CY, Withana NP et al (2012) Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 18:1224\u20131231. https:\/\/doi.org\/10.1038\/nm.2830","journal-title":"Nat Med"},{"key":"1568_CR17","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1158\/2326-6066.CIR-15-0065","volume":"3","author":"J Rautela","year":"2015","unstructured":"Rautela J, Baschuk N, Slaney CY et al (2015) Loss of host type-I IFN signaling accelerates metastasis and impairs NK-cell antitumor function in multiple models of breast cancer. Cancer Immunol Res 3:1207\u20131217. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0065","journal-title":"Cancer Immunol Res"},{"key":"1568_CR18","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202050162","author":"KL Owen","year":"2020","unstructured":"Owen KL, Gearing LJ, Zanker DJ et al (2020) Prostate cancer cell\u2010intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. EMBO Rep. https:\/\/doi.org\/10.15252\/embr.202050162","journal-title":"EMBO Rep"},{"key":"1568_CR19","doi-asserted-by":"publisher","first-page":"11917","DOI":"10.1073\/pnas.0502188102","volume":"102","author":"LFL Coelho","year":"2005","unstructured":"Coelho LFL, de Freitas Almeida GM, Mennechet FJD et al (2005) Interferon-\u03b1 and -\u03b2 differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc Natl Acad Sci U S A 102:11917\u201311922. https:\/\/doi.org\/10.1073\/pnas.0502188102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1568_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","volume":"372","author":"AM Eggermont","year":"2008","unstructured":"Eggermont AM, Suciu S, Santinami M et al (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372:117\u2013126. https:\/\/doi.org\/10.1016\/S0140-6736(08)61033-8","journal-title":"Lancet"},{"key":"1568_CR21","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.4049\/jimmunol.1502638","volume":"198","author":"K Taleb","year":"2017","unstructured":"Taleb K, Auffray C, Villefroy P et al (2017) Chronic type I IFN is sufficient to promote immunosuppression through accumulation of myeloid-derived suppressor cells. J Immunol 198:1156\u20131163. https:\/\/doi.org\/10.4049\/jimmunol.1502638","journal-title":"J Immunol"},{"key":"1568_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51496-2","volume":"15","author":"J Holzgruber","year":"2024","unstructured":"Holzgruber J, Martins C, Kulcsar Z et al (2024) Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade. Nat Commun 15:7165. https:\/\/doi.org\/10.1038\/s41467-024-51496-2","journal-title":"Nat Commun"},{"key":"1568_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher AM, Workman CJ, Vignali DAA (2022) Interferon-\u03b3: teammate or opponent in the tumour microenvironment? Nat Rev Immunol 22:158\u2013172. https:\/\/doi.org\/10.1038\/s41577-021-00566-3","journal-title":"Nat Rev Immunol"},{"key":"1568_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl2016","volume":"384","author":"J-L Casanova","year":"2024","unstructured":"Casanova J-L, MacMicking JD, Nathan CF (2024) Interferon-\u03b3 and infectious diseases: lessons and prospects. Science 384:eadl2016. https:\/\/doi.org\/10.1126\/science.adl2016","journal-title":"Science"},{"key":"1568_CR25","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/35046102","volume":"408","author":"H Takayanagi","year":"2000","unstructured":"Takayanagi H, Ogasawara K, Hida S et al (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-\u03b3. Nature 408:600\u2013605. https:\/\/doi.org\/10.1038\/35046102","journal-title":"Nature"},{"key":"1568_CR26","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.1074\/jbc.M804812200","volume":"284","author":"Z Xu","year":"2009","unstructured":"Xu Z, Hurchla MA, Deng H et al (2009) Interferon-\u03b3 targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases. J Biol Chem 284:4658\u20134666. https:\/\/doi.org\/10.1074\/jbc.M804812200","journal-title":"J Biol Chem"},{"key":"1568_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2024.100263","volume":"10","author":"X Cui","year":"2025","unstructured":"Cui X, Liu W, Jiang H et al (2025) IL-12 family cytokines and autoimmune diseases: a potential therapeutic target? J Transl Autoimmun 10:100263. https:\/\/doi.org\/10.1016\/j.jtauto.2024.100263","journal-title":"J Transl Autoimmun"},{"key":"1568_CR28","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/sj.cgt.7701069","volume":"14","author":"H Wang","year":"2007","unstructured":"Wang H, Yang G, Timme TL et al (2007) IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther 14:819\u2013827. https:\/\/doi.org\/10.1038\/sj.cgt.7701069","journal-title":"Cancer Gene Ther"},{"key":"1568_CR29","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.4049\/jimmunol.166.8.4915","volume":"166","author":"NJ Horwood","year":"2001","unstructured":"Horwood NJ, Elliott J, Martin TJ, Gillespie MT (2001) IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol 166:4915\u20134921. https:\/\/doi.org\/10.4049\/jimmunol.166.8.4915","journal-title":"J Immunol"},{"key":"1568_CR30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S8756-3282(03)00213-8","volume":"33","author":"N Nagata","year":"2003","unstructured":"Nagata N, Kitaura H, Yoshida N, Nakayama K (2003) Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-\u03b3 possibly induced from non-T cell population. Bone 33:721\u2013732. https:\/\/doi.org\/10.1016\/S8756-3282(03)00213-8","journal-title":"Bone"},{"key":"1568_CR31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12672-024-01011-2","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu Y, Sun X, Tong Y (2024) Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity. Discov Oncol 15:170. https:\/\/doi.org\/10.1007\/s12672-024-01011-2","journal-title":"Discov Oncol"},{"key":"1568_CR32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191062","volume":"217","author":"TA Waldmann","year":"2020","unstructured":"Waldmann TA, Miljkovic MD, Conlon KC (2020) Interleukin-15 (dys)regulation of lymphoid homeostasis: implications for therapy of autoimmunity and cancer. J Exp Med 217:e20191062. https:\/\/doi.org\/10.1084\/jem.20191062","journal-title":"J Exp Med"},{"key":"1568_CR33","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/JLB.5MR0422-506R","volume":"112","author":"Y Peng","year":"2022","unstructured":"Peng Y, Fu S, Zhao Q (2022) 2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy. J Leukoc Biol 112:823\u2013834. https:\/\/doi.org\/10.1002\/JLB.5MR0422-506R","journal-title":"J Leukoc Biol"},{"key":"1568_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/cmi.2008.23","volume":"5","author":"F Tang","year":"2008","unstructured":"Tang F, Zhao L, Jiang Y et al (2008) Activity of recombinant human interleukin-15 against tumor recurrence and metastasis in mice. Cell Mol Immunol 5:189\u2013196. https:\/\/doi.org\/10.1038\/cmi.2008.23","journal-title":"Cell Mol Immunol"},{"key":"1568_CR35","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1158\/1078-0432.CCR-10-1966","volume":"16","author":"P Yu","year":"2010","unstructured":"Yu P, Steel JC, Zhang M et al (2010) Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 16:6019\u20136028. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1966","journal-title":"Clin Cancer Res"},{"key":"1568_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108677","volume":"112","author":"M Zhao","year":"2019","unstructured":"Zhao M, Luo M, Xie Y et al (2019) Development of a recombinant human IL-15\u00b7sIL-15R\u03b1\/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model. Biomed Pharmacother 112:108677. https:\/\/doi.org\/10.1016\/j.biopha.2019.108677","journal-title":"Biomed Pharmacother"},{"key":"1568_CR37","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/jcb.25726","volume":"118","author":"I Okabe","year":"2017","unstructured":"Okabe I, Kikuchi T, Mogi M et al (2017) IL-15 and RANKL play a synergistically important role in osteoclastogenesis. J Cell Biochem 118:739\u2013747. https:\/\/doi.org\/10.1002\/jcb.25726","journal-title":"J Cell Biochem"},{"key":"1568_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188670","volume":"1877","author":"AR Dosch","year":"2022","unstructured":"Dosch AR, Singh S, Nagathihalli NS et al (2022) Interleukin-1 signaling in solid organ malignancies. Biochim Biophys Acta - Rev Cancer 1877:188670. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188670","journal-title":"Biochim Biophys Acta - Rev Cancer"},{"key":"1568_CR39","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41423-025-01358-8","volume":"22","author":"C Garlanda","year":"2025","unstructured":"Garlanda C, Di Ceglie I, Jaillon S (2025) IL-1 family cytokines in inflammation and immunity. Cell Mol Immunol 22:1345\u20131362. https:\/\/doi.org\/10.1038\/s41423-025-01358-8","journal-title":"Cell Mol Immunol"},{"key":"1568_CR40","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/0008-5472.CAN-19-2080","volume":"80","author":"S Das","year":"2020","unstructured":"Das S, Shapiro B, Vucic EA et al (2020) Tumor cell\u2013derived IL1\u03b2 promotes desmoplasia and immune suppression in pancreatic cancer. Cancer Res 80:1088\u20131101. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2080","journal-title":"Cancer Res"},{"key":"1568_CR41","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1593\/neo.11332","volume":"13","author":"V Tjomsland","year":"2011","unstructured":"Tjomsland V, Sp\u00e5ngeus A, V\u00e4lil\u00e4 J et al (2011) Interleukin 1\u03b1 sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia 13:664\u2013675. https:\/\/doi.org\/10.1593\/neo.11332","journal-title":"Neoplasia"},{"key":"1568_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100608","volume":"46","author":"J Zhou","year":"2024","unstructured":"Zhou J, Ottewell PD (2024) The role of IL-1B in breast cancer bone metastasis. J Bone Oncol 46:100608. https:\/\/doi.org\/10.1016\/j.jbo.2024.100608","journal-title":"J Bone Oncol"},{"key":"1568_CR43","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1158\/1078-0432.CCR-18-2202","volume":"25","author":"C Tulotta","year":"2019","unstructured":"Tulotta C, Lefley DV, Freeman K et al (2019) Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment. Clin Cancer Res 25:2769\u20132782. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2202","journal-title":"Clin Cancer Res"},{"key":"1568_CR44","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones SA, Jenkins BJ (2018) Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol 18:773\u2013789. https:\/\/doi.org\/10.1038\/s41577-018-0066-7","journal-title":"Nat Rev Immunol"},{"key":"1568_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007530","volume":"11","author":"MF Soler","year":"2023","unstructured":"Soler MF, Abaurrea A, Azcoaga P et al (2023) New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. J Immunother Cancer 11:e007530. https:\/\/doi.org\/10.1136\/jitc-2023-007530","journal-title":"J Immunother Cancer"},{"key":"1568_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104254","volume":"359","author":"R Weber","year":"2021","unstructured":"Weber R, Groth C, Lasser S et al (2021) IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cell Immunol 359:104254. https:\/\/doi.org\/10.1016\/j.cellimm.2020.104254","journal-title":"Cell Immunol"},{"key":"1568_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113315","volume":"143","author":"Y Chen","year":"2024","unstructured":"Chen Y, Guo Y, Li S et al (2024) Tumor-derived IL-6 promotes chordoma invasion by stimulating tumor-associated macrophages M2 polarization and TNF\u03b1 secretion. Int Immunopharmacol 143:113315. https:\/\/doi.org\/10.1016\/j.intimp.2024.113315","journal-title":"Int Immunopharmacol"},{"key":"1568_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100878","volume":"4","author":"MA Huseni","year":"2023","unstructured":"Huseni MA, Wang L, Klementowicz JE et al (2023) CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep Med 4:100878. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100878","journal-title":"Cell Rep Med"},{"key":"1568_CR49","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.ejca.2010.02.026","volume":"46","author":"T Ara","year":"2010","unstructured":"Ara T, DeClerck YA (2010) Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46:1223\u20131231. https:\/\/doi.org\/10.1016\/j.ejca.2010.02.026","journal-title":"Eur J Cancer"},{"key":"1568_CR50","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s10585-014-9680-3","volume":"31","author":"Y Zheng","year":"2014","unstructured":"Zheng Y, Basel D, Chow S-O et al (2014) Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone. Clin Exp Metastasis 31:921\u2013933. https:\/\/doi.org\/10.1007\/s10585-014-9680-3","journal-title":"Clin Exp Metastasis"},{"key":"1568_CR51","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s12282-018-0853-9","volume":"25","author":"H Wakabayashi","year":"2018","unstructured":"Wakabayashi H, Hamaguchi T, Nagao N et al (2018) Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line. Breast Cancer 25:566\u2013574. https:\/\/doi.org\/10.1007\/s12282-018-0853-9","journal-title":"Breast Cancer"},{"key":"1568_CR52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2025.01.002","volume":"83","author":"A Saran","year":"2025","unstructured":"Saran A, Nishizaki D, Lippman SM et al (2025) Interleukin-17: a pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders. Cytokine Growth Factor Rev 83:35\u201344. https:\/\/doi.org\/10.1016\/j.cytogfr.2025.01.002","journal-title":"Cytokine Growth Factor Rev"},{"key":"1568_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104999","volume":"217","author":"S Wang","year":"2026","unstructured":"Wang S, Wang J, Wu S et al (2026) The central role of IL-17 in cancer stemness and immune evasion: a novel axis for overcoming immune checkpoint inhibitor resistance. Crit Rev Oncol Hematol 217:104999. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104999","journal-title":"Crit Rev Oncol Hematol"},{"key":"1568_CR54","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/blood-2008-09-177360","volume":"114","author":"I Kryczek","year":"2009","unstructured":"Kryczek I, Wei S, Szeliga W et al (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114:357\u2013359. https:\/\/doi.org\/10.1182\/blood-2008-09-177360","journal-title":"Blood"},{"key":"1568_CR55","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/1471-2407-14-225","volume":"14","author":"RL Das","year":"2014","unstructured":"Das RL, Sahraei M, Schettini JL et al (2014) Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12\/SDF-1 expression in the metastatic niches. BMC Cancer 14:225. https:\/\/doi.org\/10.1186\/1471-2407-14-225","journal-title":"BMC Cancer"},{"key":"1568_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2023.102409","volume":"86","author":"LF Alim","year":"2024","unstructured":"Alim LF, Keane C, Souza-Fonseca-Guimaraes F (2024) Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment. Curr Opin Immunol 86:102409. https:\/\/doi.org\/10.1016\/j.coi.2023.102409","journal-title":"Curr Opin Immunol"},{"key":"1568_CR57","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.bbrc.2011.03.051","volume":"407","author":"T Hamaguchi","year":"2011","unstructured":"Hamaguchi T, Wakabayashi H, Matsumine A et al (2011) TNF inhibitor suppresses bone metastasis in a breast cancer cell line. Biochem Biophys Res Commun 407:525\u2013530. https:\/\/doi.org\/10.1016\/j.bbrc.2011.03.051","journal-title":"Biochem Biophys Res Commun"},{"key":"1568_CR58","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41577-022-00796-z","volume":"23","author":"BG Nixon","year":"2023","unstructured":"Nixon BG, Gao S, Wang X, Li MO (2023) TGF\u03b2 control of immune responses in cancer: a holistic immuno-oncology perspective. Nat Rev Immunol 23:346\u2013362. https:\/\/doi.org\/10.1038\/s41577-022-00796-z","journal-title":"Nat Rev Immunol"},{"key":"1568_CR59","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massagu\u00e9","year":"2023","unstructured":"Massagu\u00e9 J, Sheppard D (2023) TGF-\u03b2 signaling in health and disease. Cell 186:4007\u20134037. https:\/\/doi.org\/10.1016\/j.cell.2023.07.036","journal-title":"Cell"},{"key":"1568_CR60","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","volume":"179","author":"S Jiao","year":"2019","unstructured":"Jiao S, Subudhi SK, Aparicio A et al (2019) Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell 179:1177\u20131190. https:\/\/doi.org\/10.1016\/j.cell.2019.10.029","journal-title":"Cell"},{"key":"1568_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2025.13574","volume":"32","author":"D Wu","year":"2025","unstructured":"Wu D, Dong S, Zhou W (2025) Insulin-like growth factor in cancer: New perspectives. Mol Med Rep 32:1\u201314. https:\/\/doi.org\/10.3892\/mmr.2025.13574","journal-title":"Mol Med Rep"},{"key":"1568_CR62","doi-asserted-by":"publisher","first-page":"38422","DOI":"10.1038\/s41598-025-22288-5","volume":"15","author":"AM Nandakumar","year":"2025","unstructured":"Nandakumar AM, Barberis A, Kim J et al (2025) IGF-1 regulates cancer cell immune evasion in prostate cancer. Sci Rep 15:38422. https:\/\/doi.org\/10.1038\/s41598-025-22288-5","journal-title":"Sci Rep"},{"key":"1568_CR63","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2015.01.007","volume":"359","author":"C-T Huang","year":"2015","unstructured":"Huang C-T, Chang M-C, Chen Y-L et al (2015) Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1\/2 phosphorylation and p38 dephosphorylation. Cancer Lett 359:117\u2013126. https:\/\/doi.org\/10.1016\/j.canlet.2015.01.007","journal-title":"Cancer Lett"},{"key":"1568_CR64","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1210\/jc.2002-020656","volume":"87","author":"J Rubin","year":"2002","unstructured":"Rubin J, Ackert-Bicknell CL, Zhu L et al (2002) IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-\u03baB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 87:4273\u20134279. https:\/\/doi.org\/10.1210\/jc.2002-020656","journal-title":"J Clin Endocrinol Metab"},{"key":"1568_CR65","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1359\/jbmr.060610","volume":"21","author":"Y Wang","year":"2006","unstructured":"Wang Y, Nishida S, Elalieh HZ et al (2006) Role of IGF-I signaling in regulating osteoclastogenesis. J Bone Miner Res 21:1350\u20131358. https:\/\/doi.org\/10.1359\/jbmr.060610","journal-title":"J Bone Miner Res"},{"key":"1568_CR66","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1158\/0008-5472.CAN-11-3061","volume":"72","author":"T Hiraga","year":"2012","unstructured":"Hiraga T, Myoui A, Hashimoto N et al (2012) Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res 72:4238\u20134249. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3061","journal-title":"Cancer Res"},{"key":"1568_CR67","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.24977","volume":"6","author":"V Jentzsch","year":"2023","unstructured":"Jentzsch V, Osipenko L, Scannell JW, Hickman JA (2023) Costs and causes of oncology drug attrition with the example of insulin-like growth factor-1 receptor inhibitors. JAMA Netw Open 6:e2324977. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.24977","journal-title":"JAMA Netw Open"},{"key":"1568_CR68","doi-asserted-by":"publisher","first-page":"1410447","DOI":"10.3389\/fonc.2024.1410447","volume":"14","author":"L Somri-Gannam","year":"2024","unstructured":"Somri-Gannam L, Meisel-Sharon S, Hantisteanu S et al (2024) IGF1R inhibition and PD-1 blockade improve anti-tumor immune response in epithelial ovarian cancer. Front Oncol 14:1410447. https:\/\/doi.org\/10.3389\/fonc.2024.1410447","journal-title":"Front Oncol"},{"key":"1568_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202501341","volume":"12","author":"M Wan","year":"2025","unstructured":"Wan M, Mei J, Cai Y et al (2025) Targeting IGF1R overcomes armored and cold tumor microenvironment and boosts immune checkpoint blockade in triple-negative breast cancer. Adv Sci 12:e01341. https:\/\/doi.org\/10.1002\/advs.202501341","journal-title":"Adv Sci"},{"key":"1568_CR70","doi-asserted-by":"publisher","first-page":"8819","DOI":"10.1073\/pnas.83.23.8819","volume":"83","author":"A Oldberg","year":"1986","unstructured":"Oldberg A, Franz\u00e9n A, Heineg\u00e5rd D (1986) Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci 83:8819\u20138823. https:\/\/doi.org\/10.1073\/pnas.83.23.8819","journal-title":"Proc Natl Acad Sci"},{"key":"1568_CR71","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1158\/0008-5472.CAN-25-1486","volume":"85","author":"Y Gu","year":"2025","unstructured":"Gu Y, Muller WJ (2025) The multifaceted role of osteopontin in modulating the tumor microenvironment. Cancer Res 85:4049\u20134061. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-1486","journal-title":"Cancer Res"},{"key":"1568_CR72","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.bbrc.2004.02.124","volume":"316","author":"T Ishii","year":"2004","unstructured":"Ishii T, Ohshima S, Ishida T et al (2004) Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. Biochem Biophys Res Commun 316:809\u2013815. https:\/\/doi.org\/10.1016\/j.bbrc.2004.02.124","journal-title":"Biochem Biophys Res Commun"},{"key":"1568_CR73","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1359\/jbmr.2002.17.8.1486","volume":"17","author":"K Suzuki","year":"2002","unstructured":"Suzuki K, Zhu B, Rittling SR et al (2002) Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res 17:1486\u20131497. https:\/\/doi.org\/10.1359\/jbmr.2002.17.8.1486","journal-title":"J Bone Miner Res"},{"key":"1568_CR74","doi-asserted-by":"publisher","first-page":"39871","DOI":"10.1074\/jbc.M111.295048","volume":"286","author":"N Tanabe","year":"2011","unstructured":"Tanabe N, Wheal BD, Kwon J et al (2011) Osteopontin signals through calcium and nuclear factor of activated T Cells (NFAT) in osteoclasts. J Biol Chem 286:39871\u201339881. https:\/\/doi.org\/10.1074\/jbc.M111.295048","journal-title":"J Biol Chem"},{"key":"1568_CR75","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1359\/jbmr.2001.16.4.652","volume":"16","author":"H Nemoto","year":"2001","unstructured":"Nemoto H, Rittling SR, Yoshitake H et al (2001) Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 16:652\u2013659. https:\/\/doi.org\/10.1359\/jbmr.2001.16.4.652","journal-title":"J Bone Miner Res"},{"key":"1568_CR76","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.ccell.2025.03.036","volume":"43","author":"J-N Cheng","year":"2025","unstructured":"Cheng J-N, Jin Z, Su C et al (2025) Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. Cancer Cell 43:1093\u20131107. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.036","journal-title":"Cancer Cell"},{"key":"1568_CR77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/imr.13230","volume":"320","author":"ZJ Bernstein","year":"2023","unstructured":"Bernstein ZJ, Shenoy A, Chen A et al (2023) Engineering the IL-4\/IL-13 axis for targeted immune modulation. Immunol Rev 320:29\u201357. https:\/\/doi.org\/10.1111\/imr.13230","journal-title":"Immunol Rev"},{"key":"1568_CR78","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev-immunol-101921-041206","volume":"41","author":"JE Allen","year":"2023","unstructured":"Allen JE (2023) IL-4 and IL-13: regulators and effectors of wound repair. Annu Rev Immunol 41:229\u2013254. https:\/\/doi.org\/10.1146\/annurev-immunol-101921-041206","journal-title":"Annu Rev Immunol"},{"key":"1568_CR79","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00262-017-2043-6","volume":"66","author":"S Ito","year":"2017","unstructured":"Ito S, Shirota H, Kasahara Y et al (2017) IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model. Cancer Immunol Immunother 66:1485\u20131496. https:\/\/doi.org\/10.1007\/s00262-017-2043-6","journal-title":"Cancer Immunol Immunother"},{"key":"1568_CR80","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41419-024-06875-4","volume":"15","author":"J Zhang","year":"2024","unstructured":"Zhang J, Dong Y, Yu S et al (2024) IL-4\/IL-4R axis signaling drives resistance to immunotherapy by inducing the upregulation of Fc\u03b3 receptor IIB in M2 macrophages. Cell Death Dis 15:500. https:\/\/doi.org\/10.1038\/s41419-024-06875-4","journal-title":"Cell Death Dis"},{"key":"1568_CR81","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1002\/jcb.23269","volume":"112","author":"J Cheng","year":"2011","unstructured":"Cheng J, Liu J, Shi Z et al (2011) Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: a novel mechanism mediating its blockade of osteoclastogenesis. J Cell Biochem 112:3385\u20133392. https:\/\/doi.org\/10.1002\/jcb.23269","journal-title":"J Cell Biochem"},{"key":"1568_CR82","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s10020-021-00411-2","volume":"27","author":"Q Jin","year":"2021","unstructured":"Jin Q, Yang H, Jing Z et al (2021) IL4\/IL4R signaling promotes the osteolysis in metastatic bone of CRC through regulating the proliferation of osteoclast precursors. Mol Med 27:152. https:\/\/doi.org\/10.1186\/s10020-021-00411-2","journal-title":"Mol Med"},{"key":"1568_CR83","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1074\/jbc.M510160200","volume":"281","author":"P Palmqvist","year":"2006","unstructured":"Palmqvist P, Lundberg P, Persson E et al (2006) Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem 281:2414\u20132429. https:\/\/doi.org\/10.1074\/jbc.M510160200","journal-title":"J Biol Chem"},{"key":"1568_CR84","doi-asserted-by":"publisher","first-page":"758","DOI":"10.4049\/jimmunol.156.2.758","volume":"156","author":"Y Onoe","year":"1996","unstructured":"Onoe Y, Miyaura C, Kaminakayashiki T et al (1996) IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 156:758\u2013764. https:\/\/doi.org\/10.4049\/jimmunol.156.2.758","journal-title":"J Immunol"},{"key":"1568_CR85","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.trecan.2023.05.003","volume":"9","author":"MA Salkeni","year":"2023","unstructured":"Salkeni MA, Naing A (2023) Interleukin-10 in cancer immunotherapy: from bench to bedside. Trends Cancer 9:716\u2013725. https:\/\/doi.org\/10.1016\/j.trecan.2023.05.003","journal-title":"Trends Cancer"},{"key":"1568_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2022.1019864","volume":"13","author":"N He","year":"2022","unstructured":"He N, Jiang J (2022) Contribution of immune cells to bone metastasis pathogenesis. Front Endocrinol 13:1\u20138. https:\/\/doi.org\/10.3389\/fendo.2022.1019864","journal-title":"Front Endocrinol"},{"key":"1568_CR87","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.bone.2007.05.016","volume":"41","author":"SG-K Mohamed","year":"2007","unstructured":"Mohamed SG-K, Sugiyama E, Shinoda K et al (2007) Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Bone 41:592\u2013602. https:\/\/doi.org\/10.1016\/j.bone.2007.05.016","journal-title":"Bone"},{"key":"1568_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2121-8-4","volume":"8","author":"KE Evans","year":"2007","unstructured":"Evans KE, Fox SW (2007) Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol 8:4. https:\/\/doi.org\/10.1186\/1471-2121-8-4","journal-title":"BMC Cell Biol"},{"key":"1568_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101325","volume":"44","author":"M Oft","year":"2019","unstructured":"Oft M (2019) Immune regulation and cytotoxic T cell activation of IL-10 agonists \u2013 preclinical and clinical experience. Semin Immunol 44:101325. https:\/\/doi.org\/10.1016\/j.smim.2019.101325","journal-title":"Semin Immunol"},{"key":"1568_CR90","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-10-3862","volume":"71","author":"I Benza\u00efd","year":"2011","unstructured":"Benza\u00efd I, M\u00f6nkk\u00f6nen H, Stresing V et al (2011) High phosphoantigen levels in bisphosphonate-treated human breast tumors promote V\u03b39V\u03b42 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res 71:4562\u20134572. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3862","journal-title":"Cancer Res"},{"key":"1568_CR91","doi-asserted-by":"publisher","first-page":"6249","DOI":"10.1158\/1078-0432.CCR-12-0918","volume":"18","author":"I Benza\u00efd","year":"2012","unstructured":"Benza\u00efd I, M\u00f6nkk\u00f6nen H, Bonnelye E et al (2012) In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger V\u03b39V\u03b42 T-cell antitumor cytotoxicity through ICAM-1 engagement. Clin Cancer Res 18:6249\u20136259. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0918","journal-title":"Clin Cancer Res"},{"key":"1568_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109030","volume":"110","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Wang P, Fu Y et al (2022) Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer. Int Immunopharmacol 110:109030. https:\/\/doi.org\/10.1016\/j.intimp.2022.109030","journal-title":"Int Immunopharmacol"},{"key":"1568_CR93","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1480301","volume":"7","author":"A Liede","year":"2018","unstructured":"Liede A, Hernandez RK, Wade SW et al (2018) An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. Oncoimmunology 7:e1480301. https:\/\/doi.org\/10.1080\/2162402X.2018.1480301","journal-title":"Oncoimmunology"},{"key":"1568_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100634","volume":"48","author":"E Mabrut","year":"2024","unstructured":"Mabrut E, Mainbourg S, Peron J et al (2024) Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases. J Bone Oncol 48:100634. https:\/\/doi.org\/10.1016\/j.jbo.2024.100634","journal-title":"J Bone Oncol"},{"key":"1568_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107858","volume":"193","author":"Y Asano","year":"2024","unstructured":"Asano Y, Yamamoto N, Demura S et al (2024) Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases. Lung Cancer 193:107858. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107858","journal-title":"Lung Cancer"},{"key":"1568_CR96","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41584-021-00584-4","volume":"17","author":"AY Chen","year":"2021","unstructured":"Chen AY, Wolchok JD, Bass AR (2021) TNF in the era of immune checkpoint inhibitors: friend or foe? Nat Rev Rheumatol 17:213\u2013223. https:\/\/doi.org\/10.1038\/s41584-021-00584-4","journal-title":"Nat Rev Rheumatol"},{"key":"1568_CR97","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006814","volume":"11","author":"F Fa\u2019ak","year":"2023","unstructured":"Fa\u2019ak F, Buni M, Falohun A et al (2023) Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer 11:e006814. https:\/\/doi.org\/10.1136\/jitc-2023-006814","journal-title":"J Immunother Cancer"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01568-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-026-01568-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01568-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:10:59Z","timestamp":1783041059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-026-01568-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1568"],"URL":"https:\/\/doi.org\/10.1007\/s00223-026-01568-w","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"106"}}